Literature DB >> 24844976

Outcomes following Boston type 1 keratoprosthesis implantation in aniridia patients at the University of Montreal.

Salima I Hassanaly1, Julia C Talajic2, Mona Harissi-Dagher2.   

Abstract

PURPOSE: To describe outcomes after Boston Type 1 Keratoprosthesis (KPro) surgery in aniridic eyes.
DESIGN: Retrospective, interventional case series.
SETTING: University-based tertiary care institution. PATIENT POPULATION: Twenty-six aniridic eyes of 19 patients who underwent KPro implantation by a single experienced surgeon (M.H.-D.) between October 27, 2008 and January 16, 2012. MAIN OUTCOME MEASURES: Preoperative and postoperative best-corrected visual acuity (BCVA), intraoperative and postoperative complications, and keratoprosthesis retention.
RESULTS: Mean age was 56 years (range, 28-72); 10 patients were male. Seven patients had bilateral procedures. No intraoperative complications were encountered. Preoperatively, BCVA was 20/300 or worse in all eyes. After a mean follow-up time of 28.7±13.5 months (range 4-50), the most recent BCVA was 20/200 or better in 14 eyes. Visual potential was limited by preexisting terminal glaucoma (n=2), phthisis after retinal detachment (n=4), and suprachoroidal hemorrhage (n=2). Other postoperative complications included retroprosthetic membrane formation (n=15), infectious keratitis (n=1), extrusion (n=2), and corneal melt (n=4). Uncomplicated vitritis was reported in 6 eyes. No endophthalmitis occurred in this series. Most eyes have glaucoma and are on medical treatment. The overall retention rate of the initial prosthesis was 77%.
CONCLUSIONS: The prognosis in aniridic patients after KPro is variable. Meticulous follow-up and a subspecialty team approach are of utmost importance.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24844976     DOI: 10.1016/j.ajo.2014.05.009

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

1.  Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center.

Authors:  Ghasem Yazdanpanah; Kelley J Bohm; Omar M Hassan; Faris I Karas; Abdelrahman M Elhusseiny; Manachai Nonpassopon; Muanploy Niparugs; Elmer Y Tu; Joel Sugar; Mark I Rosenblatt; Maria S Cortina; Ali R Djalilian
Journal:  Am J Ophthalmol       Date:  2019-11-12       Impact factor: 5.258

2.  Clinical outcomes and visual prognostic factors in congenital aniridia.

Authors:  Adam Jacobson; Shahzad I Mian; Brenda L Bohnsack
Journal:  BMC Ophthalmol       Date:  2022-05-25       Impact factor: 2.086

3.  Congenital aniridia: etiology, manifestations and management.

Authors:  Monica Samant; Bharesh K Chauhan; Kira L Lathrop; Ken K Nischal
Journal:  Expert Rev Ophthalmol       Date:  2016-03-09

Review 4.  Boston Type 1 Keratoprosthesis: Updated Perspectives.

Authors:  Manachai Nonpassopon; Muanploy Niparugs; Maria Soledad Cortina
Journal:  Clin Ophthalmol       Date:  2020-04-29

5.  Commentary: Long-Term Anatomical and Functional Survival of Boston Type 1 Keratoprosthesis in Congenital Aniridia.

Authors:  Yelin Yang; C Maya Tong; Andrea Dahoud; Mona Harissi-Dagher
Journal:  Front Med (Lausanne)       Date:  2021-12-23

6.  Long-Term Anatomical and Functional Survival of Boston Type 1 Keratoprosthesis in Congenital Aniridia.

Authors:  Ariann Dyer; Alix De Faria; Gemma Julio; Juan Álvarez de Toledo; Rafael I Barraquer; Maria Fideliz de la Paz
Journal:  Front Med (Lausanne)       Date:  2021-09-30

Review 7.  Clinical and molecular aspects of congenital aniridia - A review of current concepts.

Authors:  Shailja Tibrewal; Ria Ratna; Abha Gour; Sumita Agarkar; Suneeta Dubey; Suma Ganesh; Ramesh Kekunnaya; Virender Sangwan; Yutao Liu; Vanita Vanita
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

Review 8.  Boston keratoprosthesis - Clinical outcomes with wider geographic use and expanding indications - A systematic review.

Authors:  Khalid Al Arfaj
Journal:  Saudi J Ophthalmol       Date:  2015-02-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.